



Pharmacotherapy of Glioblastoma – Recent Improvements and Novel Perspectives

Guest Editors:

Dr. Magdalena Kusaczuk

Department of Pharmaceutical Biochemistry, Medical University of Białystok, 15-222 Białystok, Poland

Dr. Monika Naumowicz

Laboratory of Bioelectrochemistry, Department of Physical Chemistry, Faculty of Chemistry, University of Białystok, 15-245 Białystok, Poland

Dr. Guillermo Velasco

Department of Biochemistry and Molecular Biology, School of Biology, Complutense University, and Instituto de Investigaciones Sanitarias San Carlos (IdISSC), 28040 Madrid, Spain

Deadline for manuscript submissions:

closed (30 March 2023)



mdpi.com/si/73938

Message from the Guest Editors

Glioblastoma (GBM) is one of the most aggressive forms of cancer. Several factors, such as the presence of the blood-brain barrier, the high molecular and cellular heterogeneity of GBM, the presence within these tumors of a population of cells with stem-like properties, and the difficulties in developing specific targeted therapies, have hindered the development of effective GBM therapies. Remarkably, plasma membrane properties have a high impact on drug-membrane interactions and drug permeability, and therefore should be considered for the design of novel therapeutic approaches against GBM.

Authors are invited to submit original and review articles covering all aspects of emerging pharmacotherapeutic strategies to fight GBM. These include, but are not limited to, pharmaceutical nanotechnology, nanocarriers, immunotherapy, epigenetic modifiers, innovative analytical approaches, and natural-product-based drugs.

investigational therapies
pharmacological epigenetic modifiers
targeted therapy
nanotechnology
natural products
immunotherapy
resistance to therapy
glioma stem-like cells
electroanalytical methods
liposomes

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma